» Articles » PMID: 38690274

Clinical and Immunological Comparison of COVID-19 Disease Between Critical and Non-critical Courses: a Systematic Review and Meta-analysis

Overview
Journal Front Immunol
Date 2024 May 1
PMID 38690274
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which appeared in 2019, has been classified as critical and non-critical according to clinical signs and symptoms. Critical patients require mechanical ventilation and intensive care unit (ICU) admission, whereas non-critical patients require neither mechanical ventilation nor ICU admission. Several factors have been recently identified as effective factors, including blood cell count, enzymes, blood markers, and underlying diseases. By comparing blood markers, comorbidities, co-infections, and their relationship with mortality, we sought to determine differences between critical and non-critical groups.

Method: We used Scopus, PubMed, and Web of Science databases for our systematic search. Inclusion criteria include any report describing the clinical course of COVID-19 patients and showing the association of the COVID-19 clinical courses with blood cells, blood markers, and bacterial co-infection changes. Twenty-one publications were eligible for full-text examination between 2019 to 2021.

Result: The standard difference in WBC, lymphocyte, and platelet between the two clinical groups was 0.538, -0.670, and -0.421, respectively. Also, the standard difference between the two clinical groups of CRP, ALT, and AST was 0.482, 0.402, and 0.463, respectively. The odds ratios for hypertension and diabetes were significantly different between the two groups. The prevalence of co-infection also in the critical group is higher.

Conclusion: In conclusion, our data suggest that critical patients suffer from a suppressed immune system, and the inflammation level, the risk of organ damage, and co-infections are significantly high in the critical group and suggests the use of bacteriostatic instead of bactericides to treat co-infections.

Citing Articles

Effectiveness and tolerance of enteral nutrition in critically ill patients with COVID-19.

Perez-Cruz E, Ortiz-Gutierrez S, Castanon-Gonzalez J, Luna-Camacho Y, Garduno-Lopez J Br J Nutr. 2024; 132(11):1446-1453.

PMID: 39497429 PMC: 11660160. DOI: 10.1017/S0007114524002666.

References
1.
Gallo G, Calvez V, Savoia C . Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Press Cardiovasc Prev. 2022; 29(2):115-123. PMC: 8858218. DOI: 10.1007/s40292-022-00506-9. View

2.
Tian R, Wu W, Wang C, Pang H, Zhang Z, Xu H . Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: a single-center retrospective case control study. Sci Rep. 2020; 10(1):17524. PMC: 7567789. DOI: 10.1038/s41598-020-74465-3. View

3.
Cen Y, Chen X, Shen Y, Zhang X, Lei Y, Xu C . Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study. Clin Microbiol Infect. 2020; 26(9):1242-1247. PMC: 7280135. DOI: 10.1016/j.cmi.2020.05.041. View

4.
Palladino M . Complete blood count alterations in COVID-19 patients: A narrative review. Biochem Med (Zagreb). 2021; 31(3):030501. PMC: 8495616. DOI: 10.11613/BM.2021.030501. View

5.
Tang L, Gu S, Gong Y, Li B, Lu H, Li Q . Clinical Significance of the Correlation between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity. Engineering (Beijing). 2021; 6(10):1178-1184. PMC: 7832131. DOI: 10.1016/j.eng.2020.05.013. View